Skip to content
Governance Register
Sign inFind yourself
Find yourselfSign in
Search How it works For organisations For professionals

Edition

United KingdomIrelandUnited States (current)New ZealandCanadaAustraliaScotlandNorthern Ireland
US nonprofit · EIN 811547477 · Blue Bell, PAiSource and licenceOrganisation record IRS Exempt Organizations Business Master File (EIN 811547477) - NTEE activity code, address.Board and officers IRS Form 990 annual filings, Part VII (directors, trustees, officers, key employees), read year by year to observe tenure.Latest return IRS Form 990 series e-file data - 990 for the year to 31 December 2025: assets, liabilities, staff, website, telephone, pay.Renewal outlook Computed by Governance Register from the observed filing history and filed revenue (us-approach-v4-clean). Not a statement that the organisation is recruiting.Principal officer IRS Form 990-N (e-Postcard) - principal officer named for tax year 2021.Deductibility IRS Publication 78 data (code PC), downloaded 18 October 2026.Licence US Federal Government public domain.How we handle data

Oxfendazole Development Group

Donations deductible
Revenue
$9k
year to 31 December 2025
Expenses
$227k
year to 31 December 2025
Total assets
$100k
$0 liabilities
Net assets
$100k
assets less liabilities
Directors and trustees
5
3.6y av
Staff
0
9 volunteers
Left since last filing
0
no seats appear to have opened
Voting members
5
reported in Part VI
How am I connected?

Oxfendazole Development Group's network

5 peoplei5 people on this map.The large node is the subject of this page. Solid lines are what the register itself records (5). Form 990 filings give names without a person identifier; SEC insider filings carry a CIK.

The board

5 listediTime on the board is observed from the annual filings: the IRS files no appointment date, so the bar counts years from the first filing the person appears on - a lower bound, not a filed start date. Names are exactly as filed. The IRS publishes no person identifier, so this edition does not yet link a person across organisations.Tenure and departures are observed across annual filings. Observed tenure is a lower bound - a member may have joined before the first year on record. The organisation reported 5 voting members of its governing body on its latest Form 990 Part VI, which matches the board listed here.
NameRole as filedSinceOn the board
Ellen CoddTreasurer Board Member2022
4 yrs
Javier BustosBoard member2025
1 yr
R John HortonPresident Board Member2022
4 yrs
Robert H GilmanBoard Member2022
4 yrs
Timothy GearySecretary Board member2023
3 yrs
Under 5 years5 to 6 years6 years or more

Pay and hours

year to 31 December 2025iFrom Part VII of the Form 990: compensation reported for each officer, director, trustee, key employee and highest-paid staff member, and the average hours a week they report. Most board members are unpaid; a blank means nothing was reported. Pay from related organisations is shown separately.
NameTitle as filedHours a weekPay from the organisationRelated organisationsOther
R John HortonPresident Board Member4$0
Ellen CoddTreasurer Board Member15$0
Robert H GilmanBoard Member2$0
Timothy GearySecretary Board member3$0
Javier BustosBoard member2$0

No pay was reported for anyone in Part VII on this return.

About

Legal name
Oxfendazole Development Group
EIN
811547477
Address
736 Cathcart Rd, Blue Bell, PA, 19422-1411
State
Pennsylvania
Mission
The Oxfendazole Development Group is a 501c3 nonprofit organization formed and operated exclusively for charitable purposes specifically for the purpose of engaging in research and development of pharmaceutical treatments to help eliminate neglected tropical diseases NTDs and to facilitate access to such treatments for individuals in need. (as filed on the Form 990)
Activity (NTEE)
H80 Medical research
IRS classification
501(c)03 (tax-exempt under section 501(c)(3) where shown)
Classified purpose
Medical Research
Size band
4 (IRS master file code)
Formed
2016
Principal officer
R John Horton (as named on the Form 990)
IRS ruling date
1 July 2016
Status
Code 01 (unconditional exemption)
Form 990 filings on record
3, latest 2025
IRS Publication 78
PC (contributions deductible)

Most connected

Longest observed on the filings

≥4years on the filingsEllen Codd
≥4years on the filingsR John Horton
≥4years on the filingsRobert H Gilman
≥3years on the filingsTimothy Geary

Latest return

year to 31 December 2025iFigures from the newest Form 990 or 990-EZ in the IRS e-file releases of 2025 and 2026, for the year ending 31 December 2025. US dollars, as filed.
Total assets
$100k
Total liabilities
$0
Net assets or fund balances
$100k
Contributions and grants received
$935
Program service revenue
$0
Employees
0
Volunteers
9

State registration

1 entityiBusiness-entity registers published by US states. These records are matched to this organisation by name and state, not by EIN, and are labelled as likely matches. Street addresses are not shown.
Oxfendazole Development Group likely matchiMatched by exact name and state (and ZIP where shown). State registers do not publish EINs, so this is not a confirmed match. Source: Pennsylvania Department of State, business entities (data.pa.gov xvd7-5r2c). Licence: public domain. Data last fetched 18 October 2026.
State
Pennsylvania
Entity type
Domestic Nonprofit Corporation
Status
Active
Formed
10 February 2016
Registered agent
Not stated

Officers (8)

  • ellen codd Treasurer
  • ellen codd Governor
  • javier bustos Governor
  • r john horton President
  • r john horton Governor
  • robert gilman Governor
  • timothy geary Secretary
  • timothy geary Governor

City and state of officers are not held in this extract.